Overview

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

Status:
Not yet recruiting
Trial end date:
2039-04-01
Target enrollment:
Participant gender:
Summary
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
Phase:
Phase 1
Details
Lead Sponsor:
Poseida Therapeutics, Inc.